Skip to main content
. 2011 Oct 15;124(20):3515–3524. doi: 10.1242/jcs.091140

Fig. 3.

Fig. 3.

Melusin-bound ERK1/2 activation requires FAK and IQGAP1. (A) ERK1/2 kinase assays performed on melusin immunocomplexes obtained from MelTG hearts after AB for 10 minutes or sham operation, in the absence or presence of the FAK inhibitor PF573228 (0.1 μM). ERK1/2 kinase activity was revealed by western blot analysis with anti-phosphorylated ELK1 (Ser338; n=4/group). (B) FAK kinase assays performed on melusin immunocomplex obtained from MelTG hearts after AB for 10 minutes or sham operation. FAK kinase activity was assayed using GST–FAK378–406 as a substrate, and revealed by western blot analysis with anti-phosphorylated-FAK (Tyr397; n=3/group). Melusin-null hearts were used as negative controls. (C) FAK kinase activity measured on FAK immunocomplexes obtained from wild-type (WT) hearts after AB for 10 minutes or sham operation. FAK kinase activity was revealed by western blotting with anti-phosphorylated-FAK (Tyr397; n=4/group). (D) ERK1/2 kinase assay performed on melusin immunocomplex obtained from MelTG and MelTG/Iqgap1-null (MelTG/IQ−/−) hearts after AB for 10 minutes or sham operation. ERK1/2 kinase activity was revealed by western blot analysis with anti-phosphorylated ELK1 (Ser338; n=4/group). Melusin-null hearts were used as negative controls.